Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q20707053> ?p ?o }
Showing triples 1 to 47 of
47
with 100 triples per page.
- Q20707053 subject Q7336348.
- Q20707053 subject Q8617855.
- Q20707053 abstract "Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.".
- Q20707053 atcPrefix "None".
- Q20707053 casNumber "926277-68-1".
- Q20707053 iupacName "(N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide)".
- Q20707053 pubchem "72941953".
- Q20707053 thumbnail Modimelanotide.svg?width=300.
- Q20707053 wikiPageExternalLink 800023137.
- Q20707053 wikiPageExternalLink zp1480_ap214.
- Q20707053 wikiPageWikiLink Q14662364.
- Q20707053 wikiPageWikiLink Q172847.
- Q20707053 wikiPageWikiLink Q18028916.
- Q20707053 wikiPageWikiLink Q18028918.
- Q20707053 wikiPageWikiLink Q18028921.
- Q20707053 wikiPageWikiLink Q18028923.
- Q20707053 wikiPageWikiLink Q21098917.
- Q20707053 wikiPageWikiLink Q213907.
- Q20707053 wikiPageWikiLink Q286779.
- Q20707053 wikiPageWikiLink Q30612.
- Q20707053 wikiPageWikiLink Q306764.
- Q20707053 wikiPageWikiLink Q389934.
- Q20707053 wikiPageWikiLink Q410794.
- Q20707053 wikiPageWikiLink Q415353.
- Q20707053 wikiPageWikiLink Q423855.
- Q20707053 wikiPageWikiLink Q424337.
- Q20707053 wikiPageWikiLink Q4734908.
- Q20707053 wikiPageWikiLink Q4836002.
- Q20707053 wikiPageWikiLink Q6591465.
- Q20707053 wikiPageWikiLink Q7119043.
- Q20707053 wikiPageWikiLink Q7336348.
- Q20707053 wikiPageWikiLink Q824258.
- Q20707053 wikiPageWikiLink Q8386.
- Q20707053 wikiPageWikiLink Q8617855.
- Q20707053 wikiPageWikiLink Q909393.
- Q20707053 atcPrefix "None".
- Q20707053 casNumber "926277".
- Q20707053 iupacName "(N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide)".
- Q20707053 pubchem "72941953".
- Q20707053 type ChemicalSubstance.
- Q20707053 type Drug.
- Q20707053 type ChemicalObject.
- Q20707053 type Thing.
- Q20707053 type Q8386.
- Q20707053 comment "Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors.".
- Q20707053 label "Modimelanotide".
- Q20707053 depiction Modimelanotide.svg.